![]() |
市場調査レポート
商品コード
1614783
OCS-01市場:市場規模、予測、新たな洞察-2032年OCS-01 Market Size, Forecast, and Emerging Insight - 2032 |
||||||
カスタマイズ可能
適宜更新あり
|
OCS-01市場:市場規模、予測、新たな洞察-2032年 |
出版日: 2024年12月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
OCS-01は新規の高濃度デキサメタゾン外用剤で、防腐剤を含みません。OCS-01はオキュリス社独自の可溶性ナノ粒子技術(SNP)を用いて開発されました。SNPは眼内薬物キャリアとして作用し、薬物のバイオアベイラビリティを高めます。本剤は、非侵襲的な局所治療薬としての製剤化、眼表面でのより長い滞留時間、関連する眼組織でのバイオアベイラビリティの向上を可能にする独自のプラットフォームであるOPTIREACH可溶化技術を用いて開発されました。
今後数年間で、術後痛の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新規アプローチに焦点を当てた治療法を開発し、課題を評価し、OCS-01の優位性に影響を与える可能性のある機会を模索しています。術後疼痛を対象とした他の新興製品は、OCS-01と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国におけるOCS-01市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"OCS-01 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about OCS-01 for Postoperative pain in the seven major markets. A detailed picture of the OCS-01 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OCS-01 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OCS-01 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.
OCS-01 is a novel, high-concentration, preservative-free, topical formulation of dexamethasone. It was developed using Oculis' proprietary Soluble NanoParticle technology (SNP), which acts as an ocular drug carrier to enhance the bioavailability of drugs. It has been developed using the OPTIREACH solubilizing technology, a proprietary platform that enables the formulation of drugs as noninvasive topical treatments, a longer residence time on the eye surface, and enhances their bioavailability in the relevant eye tissues.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
OCS-01 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of OCS-01 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of OCS-01 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.